Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial - Takeaways - MDSpire

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

  • By

  • Nina Magnolo

  • Jennifer Soung

  • John Frew

  • Antonio Costanzo

  • Hiram Ruiz-Santiago

  • Kilian Eyerich

  • Mar Llamas-Velasco

  • Michael Bukhalo

  • Raja K. Sivamani

  • Angela Moore

  • Tianshuang Wu

  • Jiaheng Xie

  • Manish Patel

  • Doug Ashley

  • Blair Kaplan

  • Vassilis Stakias

  • Ramon Espaillat

  • Richard B. Warren

  • May 17, 2026

  • 0 min

Share

  • 1

    The IMMpactful study compared the safety and efficacy of Risankizumab (RZB) and Deucravacitinib (DEU) in biologic-naïve adults with moderate plaque psoriasis.

  • 2

    RZB demonstrated significantly higher rates of achieving PASI 90 and sPGA 0/1 compared to DEU at week 16, indicating superior efficacy.

  • 3

    Patients treated with RZB also reported better quality of life outcomes, achieving higher DLQI 0/1 scores and TSQM scores than those on DEU.

  • 4

    The study provides evidence that RZB meets modern treatment goals more effectively than DEU without introducing new safety concerns.

  • 5

    This research addresses a critical gap in treatment options for moderate psoriasis, aiding clinicians in selecting first-line systemic therapies.

Original Source(s)

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

  • by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

  • May 17, 2026

Related Content

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)